Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway
出版年份 2019 全文链接
标题
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway
作者
关键词
-
出版物
JOURNAL OF IMMUNOLOGY
Volume 203, Issue 8, Pages 2043-2048
出版商
The American Association of Immunologists
发表日期
2019-09-19
DOI
10.4049/jimmunol.1801327
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
- (2018) Malik Bisserier et al. BLOOD
- Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia
- (2018) Md Kamrul Hasan et al. BLOOD
- Signalling for B cell survival
- (2018) Edina Schweighoffer et al. CURRENT OPINION IN CELL BIOLOGY
- Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma
- (2018) Jian Yu et al. Oncotarget
- Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells
- (2018) Md Kamrul Hasan et al. LEUKEMIA
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
- (2017) Xiaohong Zhao et al. Nature Communications
- Mantle Cell Lymphoma
- (2016) Chan Yoon Cheah et al. JOURNAL OF CLINICAL ONCOLOGY
- Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
- (2016) Arati A. Inamdar et al. Oncotarget
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
- (2015) Michael Y. Choi et al. Clinical Lymphoma Myeloma & Leukemia
- Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
- (2015) Jian Yu et al. JOURNAL OF CLINICAL INVESTIGATION
- Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
- (2014) Jiao Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
- (2014) Suping Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- Targeting pathological B cell receptor signalling in lymphoid malignancies
- (2013) Ryan M. Young et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers
- (2012) Suping Zhang et al. AMERICAN JOURNAL OF PATHOLOGY
- CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
- (2012) Elaine Y. Chung et al. JOURNAL OF CLINICAL INVESTIGATION
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More